We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Nanofluidic Device Traps and Concentrates Pathogenic Bacteria

By LabMedica International staff writers
Posted on 31 Mar 2020
A nanofluidic device containing stacked magnetic beads of different sizes has been developed to efficiently trap, concentrate, and retrieve Escherichia coli (E. More...
coli) bacteria from liquid suspensions.

The miniaturized, inexpensive, and transparent device developed by investigators at Rutgers University (Rochester, NY, USA) and the Rochester Institute of Technology (NY, USA) is easy to fabricate and operate, making it ideal for pathogen separation in both laboratory and point-of-care settings.

The investigators used computational fluid dynamics, three-dimensional tomography technology, and machine learning to probe and explain the effects of bead stacking in a small three-dimensional space with various flow rates. Ultimately, a combination of beads with different sizes was utilized to achieve a high capture efficiency (approximately 86%) with a flow rate of 50 microliters per minute.

In addition, the investigators showed that the high deformability of the device enabled retrieval of an E. coli sample from a bacterial suspension by applying a higher flow rate followed by rapid magnetic separation. This unique function was also utilized to concentrate E. coli cells from the original bacterial suspension. An on-chip concentration factor of about 11 times was achieved by inputting 1300 microliters of the E. coli sample and then concentrating it down to 100 microliters.

The new device is expected to play an important role in the identification and isolation of drug resistant strains of bacteria, from which at least 700,000 people die each year, including 230,000 deaths from multidrug-resistant tuberculosis.

"The rapid identification of drug-resistant bacteria allows health care providers to prescribe the right drugs, boosting the chances of survival," said contributing author Dr. Ruo-Qian (Roger) Wang, assistant professor of civil and environmental engineering at Rutgers University.

The nanofluidic device was described in the February 19, 2020, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Rutgers University
Rochester Institute of Technology



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.